Indaptus Therapeutics, Inc. (INDP)

NCM – Real Time Price. Currency in USD

1.73

-0.03 (-1.70%)

At close: May 12, 2026, 4:00 PM EDT

1.79

+0.04 (2.29%)

Pre-market: May 13, 2026, 7:00 AM EDT

29.12.2025

Indaptus Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar

NEW YORK, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announces it has entered into a $6 million securities purchase agreement with investor, David E. Lazar, for the purchase of non-voting convertible preferred stock of the Company. Mr. Lazar has been appointed Indaptus' Co-Chief Executive Officer and Chairman of the Board. Jeffrey Meckler will continue as Co-CEO and remain on the Board.

17.11.2025

Indaptus Therapeutics Chief Scientific Officer Dr. Michael Newman to Present at the Donor Selection & Cell Source Summit

NEW YORK, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announced that Michael Newman, Ph.D., Founder and Chief Scientific Officer, will present at the 3rd Donor Selection & Cell Source Summit, taking place November 19–20, 2025, in San Diego, California.

12.11.2025

Indaptus Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

NEW YORK, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announces financial results for the third quarter ended September 30, 2025, and provides a corporate update. Jeffrey Meckler, Indaptus Therapeutics' Chief Executive Officer, commented, “We have completed the Safety Lead-In cohort, dosing six evaluable participants with the combination of Decoy20 and tislelizumab.

Videos

No Data

There is no data to display

Press releases

29.12.2025

Indaptus Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar

12.11.2025

Indaptus Therapeutics, Inc. (INDP)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Indaptus Therapeutics, Inc. (INDP)

Indaptus Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar

Indaptus Therapeutics Chief Scientific Officer Dr. Michael Newman to Present at the Donor Selection & Cell Source Summit

Indaptus Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Videos

No Data

Press releases

Indaptus Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar

Indaptus Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Indaptus Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar

Indaptus Therapeutics Chief Scientific Officer Dr. Michael Newman to Present at the Donor Selection & Cell Source Summit

Indaptus Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Videos

No Data

Press releases

Indaptus Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar

Indaptus Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Search stocks

Indaptus Therapeutics, Inc. (INDP)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Indaptus Therapeutics, Inc. (INDP)

Indaptus Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar

Indaptus Therapeutics Chief Scientific Officer Dr. Michael Newman to Present at the Donor Selection & Cell Source Summit

Indaptus Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Videos

No Data

Press releases

Indaptus Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar

Indaptus Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Indaptus Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar

Indaptus Therapeutics Chief Scientific Officer Dr. Michael Newman to Present at the Donor Selection & Cell Source Summit

Indaptus Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Videos

No Data

Press releases

Indaptus Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar

Indaptus Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update